Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... Barnhardt Manufacturing Company has earned the ... Cotton . The USDA Certified Biobased Product Label verifies ... or exceeds levels set by USDA. Biobased products are ... significant part of agricultural, forestry, or marine ingredients. ... be immediately identified as a USDA certified BioPreferred ...
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... a new explanation for differences in the severity of mental illness ... more serious the handicap. The genetic defect is situated on the ... copies of the GDI1 gene that is responsible. The results are ... and are the result of work by the group of Guy ...
... Calif., Dec. 11 Marrone Bio Innovations (MBI) today ... Mr. Chris Hildreth joined MBI as Senior Vice President ... commercial aspects of the company, including sales, marketing, and ... MBI as Vice President of Process Development, and leads ...
... Dendreon Corporation (Nasdaq: DNDN ) announced today that it has ... stock at a price to the public of $24.75 per share. ... purchase up to an additional 2,250,000 shares of common stock to ... on December 15, 2009, subject to customary closing conditions. , J. ...
Cached Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/18/2014)... Colo., USA A new GSA Bulletin ... the lower Rio Puerco and Chaco Wash in northern ... rings from salt cedar and willow, investigators were able ... or greater. They then combined this data with aerial ... the history of these arroyos. , Arroyos are deep, ...
(Date:9/18/2014)... system that can operate inside the bore of an ... a biomedical research partnership program at Brigham and Women,s ... the robot, in conjunction with real-time MRI images, can ... and less discomforting for the patient. The novel system ... with greater precision. , Developed by a team of ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... 3, 2009 Two scientists whose work has led to ... dystrophy have been chosen to receive the 2009 March of ... Ph.D. and Louis M. Kunkel, Ph.D., will share the 2009 ... genes and proteins that cause muscular dystrophy, a disorder in ...
... 2009 Signal Hill, CA Tom Bowman, ... helps organizations make sustainable transformations, has written a ... programs required to encourage sustainable behaviors and drive ... paper, entitled "A Turning Point in Climate Change ...
... BALTIMOREPediatric experts from Children,s National Medical Center ... at the 2009 Pediatric Academic Societies Annual Meetingthe largest ... Presenters and topics include: ... will present the outcomes of her innovative and successful ...
Cached Biology News:March of Dimes awards $250,000 prize to scientists unraveling the causes of muscular dystrophy 2Children's National experts present at Pediatric Academic Societies' Annual Meeting 2Children's National experts present at Pediatric Academic Societies' Annual Meeting 3
... Duo is suitable for use with a ... solvents through to water and some of ... concentrator capable of removing water and organic ... including tubes, microplates, vials and round bottom ...
... Precision Model 410 is a four-channel general purpose ... small signals from sources which may have a ... channel consists of a high gain/low noise amplifier, ... and an output offset control. A control knob ...
Proliferin (N-14)...
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
Biology Products: